Who are Dichloroacetate (DCA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Etavopivat C, Etavopivat B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dichloroacetate-dca.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Dichloroacetate (DCA) — Competitive Intelligence Brief

Dichloroacetate (DCA) (Dichloroacetate (DCA)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pyruvate dehydrogenase kinase inhibitor. Area: Oncology.

phase 3 Pyruvate dehydrogenase kinase inhibitor Pyruvate dehydrogenase kinase (PDK) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dichloroacetate (DCA) (Dichloroacetate (DCA)) — University of Florida. Dichloroacetate inhibits pyruvate dehydrogenase kinase, shifting cellular metabolism from glycolysis toward oxidative phosphorylation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dichloroacetate (DCA) TARGET	Dichloroacetate (DCA)	University of Florida	phase 3	Pyruvate dehydrogenase kinase inhibitor	Pyruvate dehydrogenase kinase (PDK)
Etavopivat C	Etavopivat C	Novo Nordisk A/S	phase 3	Pyruvate dehydrogenase kinase inhibitor	PDK (pyruvate dehydrogenase kinase)
Etavopivat B	Etavopivat B	Novo Nordisk A/S	phase 3	Pyruvate dehydrogenase kinase inhibitor	PDK (Pyruvate dehydrogenase kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pyruvate dehydrogenase kinase inhibitor class)

Novo Nordisk A/S · 2 drugs in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dichloroacetate (DCA) — Competitive Intelligence Brief. https://druglandscape.com/ci/dichloroacetate-dca. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab